Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy

Crohn's disease (moderate to severe) - vedolizumab: final appraisal determination information

Crohn's disease (moderate to severe) - vedolizumab: final appraisal determination document (PDF 544 KB)

Crohn's disease (moderate to severe) - vedolizumab: committee papers information

Crohn's disease (moderate to severe) - vedolizumab: committee papers (PDF 5.44 MB)

Crohn's disease (moderate to severe) - vedolizumab: appraisal consultation

Crohn's disease (moderate to severe) - vedolizumab: appraisal consultation document (PDF 708 KB)

Crohn's disease (moderate to severe) - vedolizumab: committee papers information

Crohn's disease (moderate to severe) - vedolizumab: committee papers part 1 (PDF 10.23 MB)

Crohn's disease (moderate to severe) - vedolizumab: committee papers part 2 (PDF 4.43 MB)

Crohn's disease (moderate to severe) - vedolizumab: final scope (PDF 156 KB)

Crohn's disease (moderate to severe) - vedolizumab: final matrix (PDF 156 KB)

Crohn's disease (moderate to severe) - vedolizumab: NICE response to comments on the draft matrix and scope (PDF 317 KB)

Crohn's disease (moderate to severe) - vedolizumab: equality impact assessment (PDF 172 KB)

Crohn's disease (moderate to severe) - vedolizumab: draft scope for re-scope consultation (post referral) (PDF 161 KB)

Crohn's disease (moderate to severe) - vedolizumab: draft matrix for re-scope consultation (post referral) (PDF 151 KB)

Crohn's disease (moderate to severe) - vedolizumab: draft scope for consultation (pre-referral) - October 2013 (PDF 110 KB)

Crohn's disease (moderate to severe) - vedolizumab: provisional matrix (pre-referral) - October 2013 (PDF 101 KB)